[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100596570":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":22,"locations":32,"responsibleParty":46,"collaborators":11,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":11,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":11,"enrollmentInfo":58,"targetDuration":11,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":11,"overallStatus":34,"whyStopped":11,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"The First Hospital of Jilin University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"venetoclax + Azacitidine","EXPERIMENTAL",null,[13],"Drug: VEN (Venetoclax)",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","VEN (Venetoclax)","Enrolled patients will receive: Venetoclax: 100 mg on Day 1, 200 mg on Day 2, and 400 mg on Days 3-14. Azacitidine: 75 mg\u002Fm² on Days 1-7. Cycle duration: 28 days Total cycles: 1 to 2 cycles",[9],[21],"Azacitidine",[23,28],{"name":24,"role":25,"phone":26,"phoneExt":11,"email":27},"Yehui Tan","CONTACT","8615948027438","yhtan@jlu.edu.cn",{"name":29,"role":25,"phone":30,"phoneExt":11,"email":31},"Yuying Li","8613944135650","lyying1001@jlu.edu.cn",[33],{"facility":5,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":11},"RECRUITING","Changchun","Jilin","130000","China","CN",{"type":41,"coordinates":42},"Point",[43,44],125.32278,43.88,{"lat":44,"lon":43},{"type":47,"investigatorFullName":24,"investigatorTitle":48,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"SPONSOR_INVESTIGATOR","Professor","100596570","phase-2-clinical-study-of-venetoclax-combined-with-azacitidine-as-bridging-therapy-prior-to-hematopoietic-stem-cell-transplantation-in-patients-with-higher-risk-myelodysplastic-syndromes-100596570",false,"NCT07047183","Clinical Study of Venetoclax Combined With Azacitidine as Bridging Therapy Prior to Hematopoietic Stem Cell Transplantation in Patients With Higher-Risk Myelodysplastic Syndromes","A Single-Arm, Prospective Clinical Study of Venetoclax Combined With Azacitidine Followed by Bridging Transplantation in Patients With High-Risk Myelodysplastic Neoplasms With Increased Blasts 2 (MDS-IB2)","Inclusion Criteria:\n\n1. Newly diagnosed MDS confirmed by morphological and immunophenotypic analysis of bone marrow；\n2. Age ≥18 years, any gender；\n3. Bone marrow blasts ≥10%；\n4. IPSS-R score \\>4.5；\n5. ECOG performance status 0-2；\n6. Scheduled for allogeneic hematopoietic stem cell transplantation (allo-HSCT)；\n7. Adequate major organ function：\n\n   * Cardiac: LVEF ≥50%\n   * Hepatic: Bilirubin ≤1.5×ULN\n   * AST\u002FALT ≤2.5×ULN\n   * Renal: Creatinine clearance ≥60 mL\u002Fmin；\n8. Written informed consent provided by the patient or legally authorized representative.\n\nExclusion Criteria:\n\n1. Extramedullary disease involvement；\n2. Hypersensitivity to any study drugs；\n3. Clinically significant hepatic\u002Frenal dysfunction exceeding inclusion thresholds；\n4. Severe cardiac disease, including congestive heart failure, myocardial infarction, and cardiac insufficiency;\n5. Concurrent malignant tumors of other organs, which can be enrolled if previously cured;\n6. Active tuberculosis or HIV infection;\n7. Concomitant hematologic disorders;\n8. Pregnancy or lactation;\n9. Inability to comply with protocol requirements;\n10. Concurrently participating in other clinical studies.","ALL","18 Years",{"count":59,"type":60},46,"ESTIMATED","INTERVENTIONAL",[63],"PHASE2","A Single-Arm, Prospective Clinical Study of Venetoclax Combined with Azacitidine Followed by Bridging Transplantation in Patients with High-Risk Myelodysplastic Neoplasms with Increased Blasts 2 (MDS-IB2)",[66,67],"Myelodysplastic Neoplasms","Transplantation","2025-08-05",{"date":70,"type":71},"2025-08-08","ACTUAL",{"date":73,"type":71},"2025-07-01",{"date":75,"type":60},"2029-06-30",{"name":24,"class":6},1]